{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Miller KD"],"funding":["NCI NIH HHS"],"pagination":["2621-2629"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6118403"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(25)"],"pubmed_abstract":["Purpose Bevacizumab improves progression-free survival but not overall survival in patients with metastatic breast cancer. E5103 tested the effect of bevacizumab in the adjuvant setting in patients with human epidermal growth factor receptor 2-negative disease. Patients and Methods Patients were assigned 1:2:2 to receive placebo with doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (arm A), bevacizumab only during AC and paclitaxel (arm B), or bevacizumab during AC and paclitaxel followed by bevacizumab monotherapy for 10 cycles (arm C). Random assignment was stratified and bevacizumab dose adjusted for choice of AC schedule. Radiation and hormonal therapy were administered concurrently with bevacizumab in arm C. The primary end point was invasive disease-free survival ("],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)."],"pmcid":["PMC6118403"],"funding_grant_id":["P30 CA008748","U10 CA180790","U10 CA180794","U10 CA180791","UG1 CA189863","U10 CA180820","UG1 CA189830","U10 CA180795","U10 CA180802","U10 CA180799","U10 CA180821","U10 CA180844","U10 CA180816","UG1 CA189859","U10 CA180847"],"pubmed_authors":["Gradishar W","Bloom S","Hobday TJ","Goldstein LJ","Tevaarwerk AJ","Hendricks CB","Brufsky AM","Le-Lindqwister NA","Miller KD","Northfelt DW","Dang CT","Mayer IA","Sledge GW","Sparano JA","O'Neill A"],"additional_accession":[]},"is_claimable":false,"name":"Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).","description":"Purpose Bevacizumab improves progression-free survival but not overall survival in patients with metastatic breast cancer. E5103 tested the effect of bevacizumab in the adjuvant setting in patients with human epidermal growth factor receptor 2-negative disease. Patients and Methods Patients were assigned 1:2:2 to receive placebo with doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (arm A), bevacizumab only during AC and paclitaxel (arm B), or bevacizumab during AC and paclitaxel followed by bevacizumab monotherapy for 10 cycles (arm C). Random assignment was stratified and bevacizumab dose adjusted for choice of AC schedule. Radiation and hormonal therapy were administered concurrently with bevacizumab in arm C. The primary end point was invasive disease-free survival (","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Sep","modification":"2025-04-22T18:29:20.609Z","creation":"2019-09-05T07:03:02Z"},"accession":"S-EPMC6118403","cross_references":{"pubmed":["30040523"],"doi":["10.1200/JCO.2018.79.2028","10.1200/jco.2018.79.2028"]}}